Clinical Trial

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-07-24
Trial Details
NCT Number NCT06545942
Lead Sponsor MOMA Therapeutics
Conditions Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Enrollment 220 participants
Start Date 2024-08-13
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23